ImmuCell Co. (NASDAQ:ICCC – Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.40 and traded as high as $4.97. ImmuCell shares last traded at $4.97, with a volume of 2,110 shares.
ImmuCell Price Performance
The company has a market capitalization of $44.29 million, a PE ratio of -9.94 and a beta of 0.62. The company has a current ratio of 3.11, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36. The stock has a fifty day simple moving average of $5.18 and a 200-day simple moving average of $4.40.
ImmuCell (NASDAQ:ICCC – Get Free Report) last posted its earnings results on Tuesday, February 25th. The biotechnology company reported $0.06 earnings per share for the quarter. The firm had revenue of $7.75 million during the quarter. ImmuCell had a negative return on equity of 15.32% and a negative net margin of 15.99%.
Institutional Inflows and Outflows
About ImmuCell
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
Featured Stories
- Five stocks we like better than ImmuCell
- How to invest in marijuana stocks in 7 stepsĀ
- Can TikTok Stock Picks Really Make You Rich?
- Investing In Automotive Stocks
- The “Quality” Rotation: Back to Basics Investing
- Insider Buying Explained: What Investors Need to Know
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.